Reported Earlier, Biogen And Stoke Highlight Zorevunersen Three-Year Open-Label Extension Data Supporting First Potential Disease-Modifying Medicine For Dravet Syndrome

Author: Benzinga Newsdesk | September 03, 2025 02:55am

– Durable reductions in seizures and continuing improvements in cognition and behavior through 3 years in patients who continued to receive zorevunersen in the open-label extension studies –

– Substantial increase in seizure-free days and continuous improvements in quality of life demonstrated in patients already taking standard of care anti-seizure medicines –

– Zorevunersen generally well tolerated across all studies –

– Data support pivotal Phase 3 EMPEROR study now underway –

Posted In: BIIB STOK